Treace Medical Concepts, Inc. (TMCI)

Market Cap	172.68M
Revenue (ttm)	218.88M
Net Income (ttm)	-50.11M
Shares Out	63.72M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	882,433
Open	2.840
Previous Close	2.800
Day's Range	2.675 - 2.990
52-Week Range	2.360 - 10.790
Beta	0.74
Analysts	Hold
Price Target	4.21 (+55.35%)
Earnings Date	Feb 26, 2026

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adduc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 477
• Stock Exchange: NASDAQ
• Ticker Symbol: TMCI
• Website: https://www.treace.com

Financial Performance

In 2024, Treace Medical Concepts's revenue was $209.36 million, an increase of 11.89% compared to the previous year's $187.12 million. Losses were -$55.74 million, 12.6% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $4.21, which is an increase of 55.35% from the latest price.

Price Target

$4.21

(55.35% upside)

Analyst Consensus: Hold